Life-threatening NLRC4-associated hyperinflammation successfully treated with IL-18 inhibition - 27/09/17
Doi : 10.1016/j.jaci.2016.10.022
Scott W. Canna, MD a, ∗ 
, Charlotte Girard, MD b, Louise Malle, BS a, Adriana de Jesus, MD, PhD a, ‡, Neil Romberg, MD c, Judith Kelsen, MD c, Lea F. Surrey, MD c, Pierre Russo, MD c, Andrew Sleight, PhD d, Eduardo Schiffrin, MD d, Cem Gabay, MD b, Raphaela Goldbach-Mansky, MD, MHS a, ‡, Edward M. Behrens, MD c
, Charlotte Girard, MD b, Louise Malle, BS a, Adriana de Jesus, MD, PhD a, ‡, Neil Romberg, MD c, Judith Kelsen, MD c, Lea F. Surrey, MD c, Pierre Russo, MD c, Andrew Sleight, PhD d, Eduardo Schiffrin, MD d, Cem Gabay, MD b, Raphaela Goldbach-Mansky, MD, MHS a, ‡, Edward M. Behrens, MD c a Intramural Research Program, National Institute of Arthritis and Musculoskeletal and Skin Diseases, Bethesda, Md
b Division of Rheumatology, Department of Internal Medicine Specialties, University Hospitals of Geneva, Geneva, Switzerland
c Children's Hospital of Philadelphia, Philadelphia, Pa
d AB2Bio, Ltd, Lausanne, Switzerland
| S.W.C., L.M., A.de.J., and R.G.-M. were supported by the Intramural Research Program of the National Institute of Arthritis, Musculoskeletal, and Skin Diseases. E.M.B. was supported by the National Institutes of Health (grant no. R01 HL112836-A1), the Nancy Taylor Foundation, and Sean Fischel Connect. C.G. is supported by Swiss National Science Foundation (grant no. 10030_152638), the Rheumasearch Foundation, and the Institute of Arthritis Research. |
|
| Disclosure of potential conflict of interest: C. Girard's institution has received a grant from AB2Bio. J. Kelsen's institution has received grant K23 from the National Institutes of Health (NIH). A. Sleight and E. Schiffrin are employed by AB2 Bio, Ltd. C. Gabay has received a grant and consulting fees from AB2 Bio for this work and consultancy fees from Roche, BMS, Merck, Pfizer, Novartis, Celgene, and Sanofi for other work. R. Goldbach-Mansky's institution has received grants from SOBI, Lilly, Regeneron, and Novartis. E. M. Behrens' institution has received a grant from the NIH, Sean Fischel Connect, and Nancy Taylor Foundation; he has received a consulting fee from AB2Bio and a grant from the NIH. The rest of the authors declare that they have no relevant conflicts of interest. |
© 2016
Publié par Elsevier Masson SAS.
Vol 139 - N° 5
P. 1698-1701 - mai 2017 Retour au numéro
Article précédent
- Midpregnancy and cord blood immunologic biomarkers, HLA genotype, and pediatric celiac disease
- Karl Mårild, Maria Vistnes, German Tapia, Øivind Midttun, Per M. Ueland, Marte K. Viken, Per Magnus, Jens P. Berg, Lars C. Stene, Ketil Størdal
- Rapamycin preferentially inhibits human IL-5+ TH2-cell proliferation via an mTORC1/S6 kinase-1–dependent pathway
- Yuzhi Yin, Alyssa Mitson-Salazar, Daniel L. Wansley, Satya P. Singh, Calman Prussin
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?